Simplywall St
Published November 20, 2026
Definium Therapeutics (DFTX) Could Be 52% Undervalued Following Third Quarter Earnings
Read the full story at Simplywall St
This means the output is very sensitive to long term margin and growth assumptions for a pre revenue biotech . ... psychedelic therapies, and any.
Surfaced by this Google Alert
- Psychedelic biotech